Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China-Reference-Cited by-同舟云学术

Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China

Published:2023-06-24 Issue:8 Volume:102 Page:2097-2107
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Fu Rongfeng^ORCID,Dong Huan^ORCID,Zhang Donglei^ORCID,Zhou Hu,Zhang Xian,Huang Yueting,Liu Xiaofan,Xue Feng,Liu Wei,Chen Yunfei,Sun Ting,Ju Mankai,Dai Xinyue,Yang Renchi^ORCID,Zhang Lei^ORCID

Funder

National Natural Science Foundation of China

Chinese Academy of Medical Sciences Initiative for Innovative Medicine

National Key Research and Development Program of China

Tianjin Municipal Science and Technology Commission Grant

the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences

Haihe Laboratory of Cell Ecosystem Innovation Fund

Clinical Research Fund of National Center for Clinical Medical Research of Hematology Diseases

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05317-z.pdf

Reference37 articles.

1. Tefferi A, Barbui T (2019) Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 94(1):133–143

2. Spivak JL (2017) Myeloproliferative Neoplasms. N Engl J Med 376(22):2168–2181

3. Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667–679

4. Tefferi A, Pardanani A (2019) Essential thrombocythemia. N Engl J Med 381(22):2135–2144

5. Szuber N et al (2019) 3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease Subgroups. Mayo Clin Proc 94(4):599–610